SCHEMBL48668

SCHEMBL48668

CC(=O)NCc1ccco1

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
EPHX2 P34913 3/20 0.62
TDP1 Q9NUW8 3/20 0.61
POLB P06746 6/20 0.59
RAB9A P51151 1/20 0.59
HSD17B10 Q99714 2/20 0.58
KDM4E B2RXH2 1/20 0.58
MAPT P10636 1/20 0.58
HPGD P15428 1/20 0.58
PTPN7 P35236 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
GAA P10253 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9301511 0.85 POLB (0.64) ALDH1A1EPHX2TDP1POLBRAB9A
SCHEMBL14694017 0.84 ALDH1A1 (0.66) ALDH1A1EPHX2TDP1POLBHSD17B10
SCHEMBL18415483 0.84 POLB (0.77) ALDH1A1EPHX2TDP1POLBRAB9A
SCHEMBL24575916 0.84 EPHX2 (0.83) ALDH1A1EPHX2TDP1POLBRAB9A
SCHEMBL1694937 0.82 ALDH1A1 (0.64) ALDH1A1EPHX2TDP1POLBHSD17B10
SCHEMBL29410065 0.82 ALDH1A1 (0.74) ALDH1A1EPHX2TDP1POLBHSD17B10
SCHEMBL1455280 0.82 ALDH1A1 (0.64) ALDH1A1EPHX2TDP1POLBHSD17B10
SCHEMBL553427 0.82 POLB (0.61) ALDH1A1EPHX2TDP1POLBRAB9A
SCHEMBL19281517 0.82 GAA (0.71) ALDH1A1POLBKDM4EMAPTMEN1
SCHEMBL18769149 0.81 HSD17B10 (0.67) ALDH1A1EPHX2TDP1POLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107567445-A It can be used as 2 phenyl 3H imidazos [4,5 B] pyridine derivates of mammal EGFR-TK ROR1 activities inhibitor 坎塞拉有限公司 2018-01-09 CN claimed
CN-107531615-A Indenyl compound, pharmaceutical composition and medical application thereof ADT制药有限责任公司 2018-01-02 CN claimed
WO-2016124553-A1 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY KANCERA AB (SE) 2016-08-11 WO claimed
CN-103827080-A Novel compounds as HIF-1alphainhibitors and manufacturing process thereof UNIV DONGGUK IND ACAD COOP 2014-05-28 CN claimed
CN-103517991-A Capture of target DNA and RNA by probes comprising intercalator molecules QUANTIBACT AS 2014-01-15 CN claimed
US-8148537-B2 Substituted acetophenones useful as PDE4 inhibitors LEO PHARMA A/S (DK) 2012-04-03 US claimed
EP-2125736-B1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA AS (DK) 2011-03-30 EP claimed
US-20100035908-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA (DK) 2010-02-11 US claimed
CN-101611005-A Be used as the acetophenones of the replacement of PDE4 inhibitor LEO PHARMA AS (DK) 2009-12-23 CN claimed
EP-2125736-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS Leo Pharma A/S (DK) 2009-12-02 EP claimed
WO-2008077404-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA A/S (DK) 2008-07-03 WO claimed
EP-1187613-A4 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2002-07-24 EP claimed
EP-1187613-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2002-03-20 EP claimed
WO-2000076505-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-12-21 WO claimed
CN-1107473-A 4-Arylamino-benzopyran and related compounds BRISTOL MYERS SQUIBB CO (US) 1995-08-30 CN claimed
JP-2076841-A None JP disclosed
EP-3356345-B1 HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS MAX PLANCK GESELLSCHAFT (DE) 2023-11-08 EP disclosed
CN-1107473-A 4-Arylamino-benzopyran and related compounds BRISTOL MYERS SQUIBB CO (US) 1995-08-30 CN disclosed
JP-H0276841-A PRODUCTION OF AMINOLEVULINIC ACIDS OSAKA ORGANIC CHEM IND LTD 1990-03-16 JP disclosed
US-4563477-A Process for the preparation of alpha-(N-pyrrolyl)-derivative acids, the salts and esters thereof; alpha-(N-pyrrolyl)-phenylacetic acids, the esters thereof, pharmaceutical compositions containing them and therapeutical applications thereof ANTIBIOTICOS, S.A. (ES) 1986-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035908-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS PDE4A, PDE4B, PDE3B ALDH1A1 457/4885EPHX2 871/4885TDP1 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.